The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry.
This week’s top deals include a Gilead Sciences’ and Arcus Biosciences’ collaboration agreement on cancer immunotherapies for $175 million and Novavax, Inc.‘s acquisition of Praha Vaccines for $167 million.
To subscribe to our Health Care M&A deals chart and more, visit our membership site. HealthCareMandA.com is devoted to healthcare merger and acquisition data for the serious analyst and investor. Every day, this service alerts you to developments in all the key segments of the health care service and technology markets.
Click here to view our quarterly and annual publications and here to view our monthly webinar series.
| Biotechnology | ||
| Acquirer | Target | Price |
| Merck & Co., Inc. | Themis Bioscience | N/A |
| Novavax, Inc. | Praha Vaccines | $167,000,000 |
| Sensei Biotherapeutics, Inc. | Alvaxa Biosciences, Inc. | N/A |
| Bristol-Myers Squibb | SNIPRx collaboration agreement | $65,000,000 |
| Gilead Sciences, Inc. | Collaboration on cancer immunotherapies | $175,000,000 |
| Pharmaceuticals | ||
| Acquirer | Target | Price |
| Eton Pharmaceuticals, Inc. | Rights to Alkindi Sprinkle | $5,000,000 |
